Empowered Funds LLC Lowers Holdings in Henry Schein, Inc. $HSIC

Key Points

• Empowered Funds LLC cut its Henry Schein stake by 59.2% in the first quarter, selling 16,735 shares and retaining 11,551 shares valued at approximately $851,000. Institutional investors collectively own 96.62% of the company.
• Henry Schein exceeded quarterly expectations, reporting $1.27 in EPS versus a $1.24 estimate and $3.46 billion in revenue, up 6.7% year over year. The company guided for fiscal 2026 EPS of $5.29–$5.39.
• Analyst sentiment remains mixed: the consensus rating is “Hold” with a $92.27 price target, although BTIG and Piper Sandler maintained bullish views with targets of $100 and $95, respectively.

Empowered Funds LLC lowered its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 59.2% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 11,551 shares of the company's stock after selling 16,735 shares during the period. Empowered Funds LLC's holdings in Henry Schein were worth $851,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of HSIC. Parallel Advisors LLC grew its holdings in Henry Schein by 12.7% during the first quarter. Parallel Advisors LLC now owns 1,314 shares of the company's stock worth $97,000 after acquiring an additional 148 shares during the period. HB Wealth Management LLC lifted its holdings in Henry Schein by 1.3% in the fourth quarter. HB Wealth Management LLC now owns 15,034 shares of the company's stock valued at $1,136,000 after acquiring an additional 191 shares during the period. Jain Global LLC boosted its position in Henry Schein by 2.0% in the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company's stock worth $708,000 after purchasing an additional 207 shares in the last quarter. Sanctuary Advisors LLC grew its stake in shares of Henry Schein by 4.5% during the 4th quarter. Sanctuary Advisors LLC now owns 4,856 shares of the company's stock worth $367,000 after purchasing an additional 209 shares during the period. Finally, Captrust Financial Advisors grew its stake in shares of Henry Schein by 3.6% during the 4th quarter. Captrust Financial Advisors now owns 6,105 shares of the company's stock worth $461,000 after purchasing an additional 210 shares during the period. Institutional investors and hedge funds own 96.62% of the company's stock.

Henry Schein Price Performance

Henry Schein stock opened at $88.13 on Monday. The stock has a market capitalization of $9.82 billion, a P/E ratio of 25.69, a P/E/G ratio of 1.68 and a beta of 0.80. The company's fifty day moving average price is $83.49 and its 200 day moving average price is $78.66. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $92.18.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.03. The company had revenue of $3.46 billion for the quarter, compared to analysts' expectations of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The firm's quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.10 EPS. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. As a group, equities research analysts anticipate that Henry Schein, Inc. will post 5.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on HSIC. BTIG Research reiterated a "buy" rating and issued a $100.00 target price on shares of Henry Schein in a research note on Wednesday, August 5th. Piper Sandler raised their price target on shares of Henry Schein from $91.00 to $95.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. Wall Street Zen cut shares of Henry Schein from a "buy" rating to a "hold" rating in a report on Sunday. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research report on Wednesday, May 6th. Finally, Mizuho dropped their target price on Henry Schein from $88.00 to $82.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $92.27.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source